RT Journal Article
SR Electronic
T1 Prevalence and clinical profile of SARS-CoV-2 infection among farmworkers in Monterey County, California: June-November, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.27.20248894
DO 10.1101/2020.12.27.20248894
A1 Joseph A. Lewnard
A1 Ana M. Mora
A1 Oguchi Nkwocha
A1 Katherine Kogut
A1 Stephen A. Rauch
A1 Norma Morga
A1 Samantha Hernandez
A1 Marcus P. Wong
A1 Karen Huen
A1 Kristin Andrejko
A1 Nicholas P. Jewell
A1 Kimberly L. Parra
A1 Nina Holland
A1 Eva Harris
A1 Maximiliano Cuevas
A1 Brenda Eskenazi
A1 on behalf of the CHAMACOS-Project-19 Study Team
YR 2021
UL http://medrxiv.org/content/early/2021/01/02/2020.12.27.20248894.abstract
AB As essential personnel, United States farmworkers have continued working in-person throughout the COVID-19 pandemic. We undertook prospective surveillance of SARS-CoV-2 infection and antibody prevalence among farmworkers in California’s Salinas Valley from 15 June to 30 November, 2020. Over this period, we observed 22.1% (1514/6864) positivity for current SARS-CoV-2 by nucleic acid detection among farmworkers tested at federally-qualified migrant and community health clinics, as compared to 17.2% (1255/7305) among other adults from the same communities (risk ratio, 1.29; 95% confidence interval, 1.20-1.37). In a nested study enrolling 1,115 farmworkers, prevalence of current infection was 27.7% among farmworkers reporting ≥1 potential COVID-19 symptom, and 7.2% among farmworkers without symptoms (adjusted odds ratio 4.17; 2.86-6.09). Prevalence of anti-SARS-CoV-2 IgG antibodies increased from 10.5% (6.0-18.4%) between 16 July-31 August to 21.2% (16.6-27.4%) between 1-30 November. The high observed prevalence of infection among farmworkers underscores the need for vaccination and other preventive interventions.Competing Interest StatementJAL has received grants and fees from Pfizer, Inc. unrelated to the submitted work.Funding StatementThis study received financial support from the Innovative Genomics Institute on the UC Berkeley Campus.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the Committee for Protection of Human Subjects at UC Berkeley.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDirect data requests to the corresponding author at jlewnard{at}berkeley.edu